Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment
Trilaciclib, a novel cyclin-dependent kinase 4/6 inhibitor, has demonstrated the ability to protect bone marrow from chemotherapy toxicity, improving patients' quality of life (QoL). This review describes the mechanism of action, efficacy, and toxicity profile of trilaciclib. Trilaciclib halts retin...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2024-08-01
|
| Saila: | Indian Journal of Medical and Paediatric Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1786017 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|